Skip to main content
Top
Published in: Familial Cancer 1/2017

01-01-2017 | Short Communication

Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?

Published in: Familial Cancer | Issue 1/2017

Login to get access

Abstract

Little is known about the change in mammograms use by women after BRCA1/2 genetic testing. We compared the rate of bilateral mammograms after and prior to BRCA1/2 testing, according to test result. Information from the Quebec Health Insurance Board database was used to identify all registered mammograms delivered between May 1, 1998 and March 31, 2012 to a cohort of 396 unaffected French Canadian women tested for BRCA1/2 mutations. Mammograms incidence density ratios were calculated using the Cox proportional hazards model for repeated events. BRCA1/2 mutation carriers and women with an inconclusive result had more mammograms after, than prior to, genetic testing. Non-carriers did not receive more mammograms. The observed increase in mammography screening in BRCA1/2 carriers is consistent with the high risk of developing breast cancer in this group. The estimation of the cancer risk associated with an inconclusive result is based on familial cancer history, and women who received this result appear to have received follow-up as if at high risk. The fact that non-carriers did not change their use of mammograms after genetic testing may possibly reflect a ‘defensive medicine’ approach by some physicians or the women’s preference.
Literature
2.
go back to reference Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, Eisen A, Howley HE, Simard J, The National Hereditary Cancer Task Force (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 29(1):45–60CrossRefPubMed Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, Eisen A, Howley HE, Simard J, The National Hereditary Cancer Task Force (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 29(1):45–60CrossRefPubMed
3.
go back to reference Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M (2010) Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 119(2):409–414. doi:10.1007/s10549-009-0611-y CrossRefPubMed Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M (2010) Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 119(2):409–414. doi:10.​1007/​s10549-009-0611-y CrossRefPubMed
8.
go back to reference Andersen PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann of Stat 10:1100–1120CrossRef Andersen PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann of Stat 10:1100–1120CrossRef
9.
go back to reference Tudiver F, Brown JB, Medved W, Herbert C, Ritvo P, Guibert R, Haggerty J, Goel V, Smith P, O’Beirne M, Katz A, Moliner P, Ciampi A, Williams JI (2001) Making decisions about cancer screening when the guidelines are unclear or conflicting. J Fam Pract 50(8):682–687PubMed Tudiver F, Brown JB, Medved W, Herbert C, Ritvo P, Guibert R, Haggerty J, Goel V, Smith P, O’Beirne M, Katz A, Moliner P, Ciampi A, Williams JI (2001) Making decisions about cancer screening when the guidelines are unclear or conflicting. J Fam Pract 50(8):682–687PubMed
10.
go back to reference Pelletier S, Wong N, El Haffaf Z, Foulkes WD, Chiquette J, Hamet P, Simard J, Dorval M (2015) Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. Genet Med. doi:10.1038/gim.2015.135 PubMed Pelletier S, Wong N, El Haffaf Z, Foulkes WD, Chiquette J, Hamet P, Simard J, Dorval M (2015) Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. Genet Med. doi:10.​1038/​gim.​2015.​135 PubMed
11.
go back to reference Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M (2012) Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. Fam Cancer 1:27–32. doi:10.1007/s10689-011-9490-6 CrossRef Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M (2012) Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. Fam Cancer 1:27–32. doi:10.​1007/​s10689-011-9490-6 CrossRef
Metadata
Title
Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
Publication date
01-01-2017
Published in
Familial Cancer / Issue 1/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9920-6

Other articles of this Issue 1/2017

Familial Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine